PCC0105005
PCC0105005 is a dual-target CGRP Receptor antagonist (IC50 = 1.01 nM) and a partial agonist of 5-HT1F Receptor (EC50 = 77.91 nM). PCC0105005 shows significant efficacy in the rat model of migraine. PCC0105005 significantly reduces the expression of CGRP and c-Fos proteins, and inhibits the phosphorylation levels of ERK and CREB. PCC0105005 can be used for research on migraine.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 2921670-99-5
- Formel: C51H63N11O4
- Molecular Weight:894.12
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Alle 5-HT Receptor Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
|
5-HT1F Receptor 77.91 nM (IC50) |
ERK |
Chemical Information
-
CAS. Nr. 2921670-99-5
-
Molecular Weight 894.12
-
Formel C51H63N11O4
-
SMILES
CN(CC1)CCC1C2=CNC3=CC=C(NC(C4=CC(C=C(C5CCN(C(N[C@H](CC6=CC(C)=C(NN=C7)C7=C6)C(N8CCN(C9CCN(C)CC9)CC8)=O)=O)CC5)C(N%10)=O)=C%10C=C4)=O)C=C32
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
- PCC0105005
- 2921670-99-5
- PCC 0105005
- PCC-0105005
- CGRP Receptor
- 5-HT Receptor
- ERK
- Epigenetic Reader Domain
- Dual-target therapeutics
- CGRP antagonists
- 5-HT1F agonists
- migraine treatment
- structure-based drug design
- pharmacokinetics
- peripheral restriction
- trigeminovascular system
- neurogenic inflammation
- pain threshold
- Inhibitor
- inhibitor
- inhibit